Skip to content

Iyuda Therapeutics

1 viewer · 30d

Total raised

$600K

+$600K this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $600K
ROUNDS
1
INVESTORS
2
FOUNDED
N/A
HQ
Owings Mills, MD
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Iyuda Therapeutics is a Maryland biotechnology company developing allogeneic cell therapies for cancer and other immune-mediated diseases, built on immunology work from Johns Hopkins. Its published patent portfolio, co-assigned with The Johns Hopkins University, covers non-engrafting, CD8-depleted allogeneic donor lymphocyte infusions designed to deliver anti-tumor activity from a mismatched donor without causing graft-versus-host disease. Related filings cover leukocyte compositions enriched for CD4+ Th1 cells and immune cells modified to suppress kinases such as BTK and ITK for adoptive cell therapy. The company is pre-commercial; its public web presence is a single placeholder page.

What sets it apart

Uses deliberately non-engrafting, CD8-depleted donor lymphocytes from an HLA-mismatched donor, aiming to separate the graft-versus-tumor effect from the graft-versus-host toxicity that limits conventional donor lymphocyte infusion.

Funding history

1 round
EquityMar 23, 2026
Form D
+$600K$600K total

Latest SEC filings

via EDGAR · CIK 0001993594
Form D · Mar 23, 2026View on EDGAR

Products

1 tracked

Non-engrafting CD8-depleted allogeneic donor lymphocyte infusion

Adoptive cell therapy

An off-the-shelf allogeneic cell therapy built from isolated leukocytes taken from an HLA-mismatched donor and depleted of CD8+ T cells, formulated so the cells do not engraft in the recipient. The approach is the subject of the company's lead patent family, filed in 2022 and published in the US, EP, WO and JP.

  • Donor leukocytes mismatched to the recipient at one or more HLA loci
  • CD8+ T cell depletion to reduce toxicity
  • Non-engrafting design so the infused cells clear rather than establish chimerism
  • Patent family co-assigned with The Johns Hopkins University

Links

WebsiteSEC EDGAR filings